Trading involves risk
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
Trading involves risk
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
English (International)
SpringWorks Therapeutics Inc
Open
SectorHealthcare
46.11 -0.15
Overview
Share price change
24h
Min
46.09
Max
46.19
Income | -5.9M -83M |
|---|---|
Sales | -12M 49M |
EPS | -1.11 |
Profit margin | -169.468 |
Employees | 368 |
EBITDA | -23M -80M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +27.11% upside |
Next Earnings | 6 Aug 2025 |
|---|
Market Cap | 5.6M 3.5B |
|---|---|
Previous open | 46.26 |
Previous close | 46.11 |
News Sentiment
By Acuity
67%
33%
339 / 382 Healthcare
Technical Score
By Trading Central
Confidence
Weak Bullish Evidence
SpringWorks Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
SpringWorks Therapeutics Inc Forecast
Price Target
By TipRanks
27.11% upside
12 Months Forecast
Average 58.75 USD 27.11%
High 84 USD
Low 47 USD
Based on 8 Wall Street analysts offering 12 month price targets forSpringWorks Therapeutics Inc - Dist in the last 3 months.
Sentiment
By Acuity
339 / 382 Healthcare
News Sentiment
Bearish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About SpringWorks Therapeutics Inc
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.
